Zevra Therapeutics (ZVRA) Operating Expenses (2014 - 2026)

Zevra Therapeutics (ZVRA) has 13 years of Operating Expenses data on file, last reported at $25.2 million in Q1 2026.

• Quarterly Operating Expenses rose 10.4% year-over-year to $25.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $92.7 million (down 4.95% YoY) and the FY2025 annual result came in at $90.4 million, down 6.81% from the prior year.
• Operating Expenses grew to $25.2 million in Q1 2026, from $23.0 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $27.2 million in Q3 2024 to a low of $5.8 million in Q1 2022.
• A 5-year average of $20.0 million and a median of $22.8 million in 2025 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2022 — Operating Expenses jumped 323.65% — and 2023, when it sank 46.12%.
• Tracing ZVRA's Operating Expenses over 5 years: stood at $11.3 million in 2022, then surged by 130.07% to $26.1 million in 2023, then dropped by 6.14% to $24.5 million in 2024, then slipped by 6.14% to $23.0 million in 2025, then advanced by 9.58% to $25.2 million in 2026.
• The last three Operating Expenses figures came in at $25.2 million (Q1 2026), $23.0 million (Q4 2025), and $20.4 million (Q3 2025), per Business Quant data.